Pharmocann Global Valuation
Is PMCN-M undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of PMCN-M when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate PMCN-M's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate PMCN-M's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PMCN-M?
Other financial metrics that can be useful for relative valuation.
What is PMCN-M's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ₪6.70m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 0.4x |
Enterprise Value/EBITDA | -0.6x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does PMCN-M's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 1.4x | ||
BARI Barak Investment House | 0.6x | n/a | ₪12.4m |
CSURE-M Cannassure Therapeutics | 3.9x | n/a | ₪42.7m |
TKUN Tikun Olam-Cannbit Pharmaceuticals | 0.7x | n/a | ₪30.6m |
SEMG Seach Medical Group | 0.4x | n/a | ₪56.1m |
PMCN-M Pharmocann Global | 0.5x | n/a | ₪6.7m |
Price-To-Sales vs Peers: PMCN-M is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (1.4x).
Price to Earnings Ratio vs Industry
How does PMCN-M's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?
Price-To-Sales vs Industry: PMCN-M is good value based on its Price-To-Sales Ratio (0.5x) compared to the Asian Pharmaceuticals industry average (2.6x).
Price to Sales Ratio vs Fair Ratio
What is PMCN-M's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 0.5x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate PMCN-M's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.